Johnson Matthey says its Fine Chemicals Division was well ahead of last year in the first quarter. The company said demand has been less affected by the recession than some other business units and it has generated income from the generic version of Adderal XR, launched in April.
Easy Bourse
Tuesday 21 July 2009
Fine chems first quarter positive for Johnson Matthey
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment